News + Font Resize -

Astellas to acquire Agensys for $387 mn
Japan | Friday, November 30, 2007, 08:00 Hrs  [IST]

Astellas Pharma Inc, said its US subsidiary, Astellas US Holding, Inc. has signed a definitive agreement on November 26, 2007, to acquire Agensys, Inc. for $387 million up front assuming approximately $30 million net cash balance at closing. In addition, Agensys' current shareholders will retain the right to receive a maximum of $150 million in accordance with Agensys' achievement of various milestones.

Upon completion of the transaction, a newly established subsidiary of Astellas US Holding, Inc. shall be merged with and into Agensys and Agensys shall become a wholly owned subsidiary of Astellas US Holding, Inc. The closing of the transaction is subject to Agensys shareholder and customary regulatory approvals, but is expected to take place by the end of December 2007.

"Astellas will continue to build our company into a strong, global pharmaceutical leader. Agensys will be the cornerstone of our biologics efforts and an integral component of building our oncology efforts within our franchise. We welcome Agensys employees to the Astellas family, said Mr. Nogimori, president and CEO, Astellas."

Astellas believes that this acquisition of Agensys will provide Astellas access to expertise and assets in fully human monoclonal antibody technologies, proprietary target molecules in the cancer field, and clinical candidate antibody pipeline. The combined company will reinforce and accelerate Astellas' antibody R&D in cancer, one of the important research therapeutic areas. Target molecules proprietary to Agensys is also expected to contribute to Astellas' in-house small molecule oncology drug discovery.

Astellas, in its medium-term plan, has declared that it will aggressively build up its antibody R&D capabilities. Astellas acquired a non-exclusive license to Regeneron's VelocImmune Technology and an access to phage display library from MorphoSys both in March 2007. It further reinforced its basis of antibody research through establishment of Advanced Biologics Section in Molecular Medicines Research Laboratories this October.

"This transaction represents a rare combination of a deal that is a win for our investors, for Astellas, and for Agensys employees. It is a real tribute to the accomplishments of the Agensys team. We were attracted by Astellas' desire to build on the core Agensys team to accelerate our discovery and commercial efforts, while working together to achieve our shared vision of building a global leader in biologics and oncology, said Dr. Rice, Chairman, president and CEO, Agensys."

Agensys is a biotechnology company specialized in therapeutic antibody research and development in cancer. It has selected candidate targets by applying differential gene expression technology to human tissues and identified 30 proprietary targets in 14 cancer types. It has rich experience in using its optimised hybridoma method (Method to generate monoclonal antibodies by hybridoma, which is derived by cell fusion of an antibody producing B cell and myeloma cell) to generate fully human monoclonal antibodies, including to challenging targets, from XenoMouse a human antibody-producing transgenic mouse in-licensed from Abgenix (currently a part of Amgen). It also has GMP manufacturing facilities producing investigational antibodies for pre-clinical and early-stage clinical studies. Agensys' pipeline includes an antibody in a phase Ib clinical trial and several candidate antibodies in late preclinical stage.

The pharmaceutical market in cancer treatment was approximately ¥1.7 trillion as of 2005 and is expected to double to approximately ¥3.4 trillion by 2015. Among these, new treatments such as antibodies, molecular targeted drugs and nucleic acid agents will expand rapidly and are anticipated to represent half of the market, the company said in a recent press statement.

Montgomery & Co. LLC is acting as financial advisor and Morrison & Foerster LLP is acting as legal counsel to Astellas in this transaction. J.P. Morgan Securities Inc. is acting as financial advisor and Latham & Watkins LLP is acting as legal counsel to Agensys in this transaction.

Agensys is a private biotechnology company located in Santa Monica, CA. It began operations in 1997 as UroGenesys, founded by oncologists at UCLA and Dr. Rice, joined by Dr. Jakobovits, an inventor of XenoMouse at Abgenix, in 1999 as CSO. The company changed its corporate name to Agensys in 2001.

Post Your Comment

 

Enquiry Form